Student Fellowship--Myasthenia Gravis or Related Neuromuscular Conditions
These fellowships are awarded annually to current medical students or graduate students interested in the scientific basis of myasthenia gravis or related neuromuscular conditions, serving both to further scientific inquiries into the nature of these disorders and to encourage more research. The stipend is up to $5,000.
Annual deadline for applications is March 15.
Myasthenia Gravis Foundation of America 1821 University Ave. W., Suite S256 St. Paul, MN 55104 Telephone: (651)917-6256 or (800)541-5454 Fax: (651)917-1835
Ara Parseghian Medical Research Foundation
Request for Applications--Niemann-Pick Type C (NP-C) disease
Niemann-Pick Type C (NP-C) disease is a genetic, neurodegenerative disorder which causes progressive deterioration of the nervous system. It usually affects children by interfering with their ability to metabolize cholesterol. Adult onset may also occur. Large amounts of cholesterol accumulate within the liver, spleen, and brain. This metabolic disorder leads to a series of neurological problems that are ultimately fatal...until a treatment is found!
POTENTIAL APPLICANTS PLEASE NOTE: If you have never received funding from the APMRF, please submit electronically a Letter of Intent as outlined below. This procedure will allow our Scientific Advisory Board to read a brief summary of your proposed research without you having to submit the full grant application.Please have this letter addressed to the APMRF Scientific Advisory Board to the Foundation office by February 13, 2009. Send the Letter of Intent as an ATTACHMENT to Glen Shepherd, Executive Director: gshepherd@parseghian.orgOur SAB will review all Letters of Intent. You will be notified by April 1 whether or not the SAB would like for you to submit the full grant application for consideration of funding. The full grant applications are due no later than April 30, 2009.The Letter of Intent should not exceed 2 pages of text (12 font single spaced) and must include the following information in this order: 1. Your name, position, title, institution, address, phone and E-mail address 2. Title of proposed research study 3. The objective of the study and hypothesis to be tested 4. The relevance to Niemann-Pick Type C disease (an extensive literature review is not required) 5. Preliminary data (this is encouraged but not essential) 6. A statement of the methods to be used and a brief description of how the results will be evaluated 7. Estimated amount of award you are requesting and whether for a one- or two-year period 8. Current financial support: List each current grant or contract you have that would overlap with the conduct of this research and how this overlap will be accommodated if APMRF funding is awarded. If there are no such grants, state “NONE”If you have questions or comments on the Letter of Intent, please contact Glen Shepherd at (520) 577-5106 or gshepherd@parseghian.org
Therapeutics Development Initiative 2009 Pre-Proposal Receipt Date: January 20, 2009 – 6:00pm US ETThe Michael J. Fox Foundation for Parkinson’s Research (MJFF) announces the launch of its Therapeutics Development Initiative (TDI) for Spring 2009, a funding mechanism to support and stimulate preclinical Parkinson’s disease research at for-profit institutions. This funding program seeks to support preclinical development of Parkinson’s disease therapies which have the potential for fundamentally altering disease course and/or improving treatment of symptoms above and beyond current standards of care. Proposals must focus on key and critical preclinical studies necessary for developing, optimizing and evaluating therapeutic strategies that if successful can move into human testing. Responsibility for the planning, direction, and execution of the proposed project will be solely that of the principal investigator who must be an employee of a for-profit entity. Academic investigators may have an advisory role in the project, but the operational and strategic ownership of the project must reside within the company. Investigators may seek up to two years of funding for preclinical development and testing of novel therapeutic approaches for the treatment or prevention of Parkinson’s disease. Please note that pre-proposals are mandatory and will be used to evaluate your proposal’s fit with the stated aims and review criteria of the RFP. All pre-proposals received in response to this program will be subjected to a triage process and only those pre-proposals deemed to be of suitable scientific merit will be invited to submit a full application. MJFF employs an expedited, abbreviated granting mechanism to accelerate discoveries and ultimately translate findings to PD patients more quickly. Conference Call MJFF will hold a 45 minute long conference call on December 16, 2008 at 12:00 PM U.S. Eastern Time to clarify and explain the Therapeutics Development Initiative 2009 program and to answer applicants' questions. To participate in this call, you must RSVP via email to conferencecalls@michaeljfox.org. Participants will receive a reply with call-in details.
While there are no restrictions as to the specific approaches to be studied under this RFP, successful applications are most likely to focus on at least one of the following categories: o Neuroprotective strategies focused on slowing or preventing the process of neuronal death. o Neuroregenerative strategies to restore or replace neuronal function. o Novel drug delivery mechanisms and/or surgical procedures. o Innovative therapeutic approaches to treat the motor and non-motor symptoms of PD, including cognitive dysfunction, autonomic dysfunction, sleep disorders, or depression among others. o Therapeutic approaches to alleviate complications of PD treatment including dyskinesias, etc.
If you would like to contact the Foundation, please call toll-free at 1-800-708-7644, or contact us by regular mail at the following address: The Michael J. Fox Foundation for Parkinson's Research Church Street Station P.O. Box 780 New York, NY 10008-0780
123next
